Edesa Biotech EV / EBITDA
Cos'è EV / EBITDA di Edesa Biotech?
EV / EBITDA di Edesa Biotech, Inc. è N/A
Qual è la definizione di EV / EBITDA?
EV / EBITDA è il valore aziendale diviso per guadagni prima di interessi, tasse, deprezzamento e ammortamento. È una misura di quanto sia costosa una azione ed è più frequentemente valida per i confronti tra le aziende rispetto al rapporto prezzo / guadagno. Misura il prezzo (sotto forma di valore d'impresa) che un investitore paga a vantaggio del flusso di cassa della società (sotto forma di EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA di aziende nel Health Care settore su NASDAQ rispetto a Edesa Biotech
Cosa fa Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Aziende con ev / ebitda simili a Edesa Biotech
- Bambuser AB (publ) ha EV / EBITDA di N/A
- Nevada Metals ha EV / EBITDA di N/A
- Elys Game Technology ha EV / EBITDA di N/A
- Velodyne Lidar ha EV / EBITDA di N/A
- Blue Sky Alternative Investments ha EV / EBITDA di N/A
- Arix Bioscience plc ha EV / EBITDA di N/A
- Edesa Biotech ha EV / EBITDA di N/A
- Shenzhen Neptunus Interlong Bio-technique ha EV / EBITDA di N/A
- Baumot AG ha EV / EBITDA di N/A
- Discovery Harbour Resources ha EV / EBITDA di N/A
- Guardion Health Sciences Inc ha EV / EBITDA di N/A
- Taronis Fuels ha EV / EBITDA di N/A
- DQ Entertainment (International) ha EV / EBITDA di N/A